Amphastar Pharmaceuticals (AMPH) to Release Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Amphastar Pharmaceuticals to post earnings of $1.01 per share and revenue of $188.78 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Amphastar Pharmaceuticals Trading Up 3.2 %

Shares of AMPH stock opened at $32.29 on Tuesday. Amphastar Pharmaceuticals has a 12-month low of $30.34 and a 12-month high of $56.38. The company has a market capitalization of $1.55 billion, a PE ratio of 10.76, a price-to-earnings-growth ratio of 2.19 and a beta of 0.81. The firm has a 50 day moving average price of $35.45 and a two-hundred day moving average price of $42.91. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Buying and Selling

In other news, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the completion of the sale, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the transaction, the executive vice president now directly owns 118,469 shares in the company, valued at $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMPH. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Piper Sandler cut Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $66.00 to $36.00 in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $50.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.